Background: The introduction of phosphodiesterase 5 (PDE5) inhibitors for the treatment of
erectile dysfunction was a landmark in the therapy of this highly prevalent male disorder …

The success of sildenafil (Viagra®; Pfizer) as an oral therapy for male erectile dysfunction
(MED) has greatly stimulated interest in phosphodiesterase (PDE)-5 inhibitors. A large …

Introduction Erectile dysfunction (ED) is a very common multidimensional disorder affecting
men worldwide. Physical illness, reaction to life stresses, or an unhappy couple relationship …

OBJECTIVE To review the pharmacologic and clinical trial data of the Food and Drug
Administration–approved phosphodiesterase 5 (PDE5) inhibitors for the treatment of erectile …

Erectile dysfunction (ED) is the persistent inability to achieve or maintain an erection
sufficient for satisfactory sexual performance. 1 According to data from the Massachusetts …

Importance to the field: Since sildenafil was introduced 10 years ago, highly selective
phosphodiesterase type 5 inhibitors (PDE5i) have changed the medical management of …

Erectile dysfunction is a prevalent disorder that not only affects men with the disorder but
also their partners. Significant improvements in the sexual health of these couples have …

Introduction: Phosphodiesterase type 5 inhibitors (PDE5-i) are used for the oral treatment of
erectile dysfunction (ED). Since the launch of sildenafil more than 15 years ago, new …

Erectile dysfunction (ED) affects the sexual lives of millions of men. The first-line oral
pharmacotherapy for most ED patients is phosphodiesterase type-5 (PDE-5) inhibitors, of …

Introduction: Phosphodiesterase type 5 inhibitors (PDE5Is) are the leading drugs for the
treatment of erectile dysfunction (ED), being recommended as a first line treatment by both …